Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)’s share price traded up NaN during trading on Thursday . The company traded as high as $6.42 and last traded at $0.00. 1,380,532 shares changed hands during trading, an increase of Infinity from the average session volume of 0 shares.

A number of equities analysts recently commented on the stock. ValuEngine raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. JMP Securities reaffirmed an “outperform” rating and set a $11.00 price target (up from $5.00) on shares of Marinus Pharmaceuticals in a research report on Tuesday, September 12th.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.02.

A hedge fund recently raised its stake in Marinus Pharmaceuticals stock. KCG Holdings Inc. boosted its position in shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by 29.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 64,539 shares of the biopharmaceutical company’s stock after buying an additional 14,692 shares during the period. KCG Holdings Inc. owned approximately 0.30% of Marinus Pharmaceuticals worth $114,000 at the end of the most recent quarter. 23.60% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.